Patents by Inventor Luoheng Qin

Luoheng Qin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250066348
    Abstract: Provided herein are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Further provided herein are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.
    Type: Application
    Filed: November 11, 2022
    Publication date: February 27, 2025
    Inventors: Jianping Wu, Luoheng QIN, Jinxin LIU
  • Publication number: 20250034133
    Abstract: Provided are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Further provided are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancers.
    Type: Application
    Filed: November 11, 2022
    Publication date: January 30, 2025
    Inventors: Jianping Wu, Luoheng QIN, Jinxin LIU, Yingtao LIU
  • Publication number: 20250026754
    Abstract: Provided are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Provided are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.
    Type: Application
    Filed: November 11, 2022
    Publication date: January 23, 2025
    Inventors: Jianping Wu, Luoheng QIN, Jinxin LIU
  • Publication number: 20240417405
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: May 6, 2022
    Publication date: December 19, 2024
    Inventors: Olivier Alexis Georges Querolle, Xuedong Dai, Wei Cai, Johannes Wilhelmus J. Thuring, Lichao Fang, Ming Li, Lianzhu Liu, Yingtao Liu, Luoheng Qin, Jianping Wu, Yanping Xu, Patrick Rene Angibaud, Helene France Solange Colombeo, Isbelle Noelle Constance Pilatte, Virginie Sophie Poncelet, Carsten Sven Kramer, Vineet Pande, Xiangjun Deng
  • Patent number: 12162862
    Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.
    Type: Grant
    Filed: August 23, 2023
    Date of Patent: December 10, 2024
    Assignee: INSILICO MEDICINE IP LIMITED
    Inventors: Xin Cheng, Yingtao Liu, Luoheng Qin
  • Patent number: 12091406
    Abstract: Described herein are KAT6A inhibitors of Formula (Ia) and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: November 13, 2023
    Date of Patent: September 17, 2024
    Assignee: INSILICO MEDICINE IP LIMITED
    Inventors: Xin Cheng, Luoheng Qin, Feng Ren
  • Publication number: 20240190839
    Abstract: The disclosure provides for small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. The disclosure further provides methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.
    Type: Application
    Filed: June 26, 2023
    Publication date: June 13, 2024
    Inventors: Jianping Wu, Luoheng Qin, Jinxin Liu
  • Publication number: 20240150374
    Abstract: Described herein are KAT6A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KAT6A.
    Type: Application
    Filed: November 13, 2023
    Publication date: May 9, 2024
    Inventors: Xin CHENG, Luoheng QIN, Feng REN
  • Publication number: 20240116899
    Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.
    Type: Application
    Filed: August 23, 2023
    Publication date: April 11, 2024
    Inventors: Xin CHENG, Yingtao LIU, Luoheng QIN
  • Publication number: 20240109880
    Abstract: Described herein are KAT6A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KAT6A.
    Type: Application
    Filed: October 13, 2023
    Publication date: April 4, 2024
    Inventors: Xin CHENG, Luoheng QIN, Feng REN
  • Patent number: 11834440
    Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: December 5, 2023
    Assignee: Insilico Medicine IP Limited
    Inventors: Xin Cheng, Yingtao Liu, Luoheng Qin
  • Patent number: 11739077
    Abstract: The disclosure provides for small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. The disclosure further provides methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: August 29, 2023
    Assignee: Insilico Medicine IP Limited
    Inventors: Jianping Wu, Luoheng Qin, Jinxin Liu
  • Patent number: 11691970
    Abstract: Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: July 4, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Haibing Guo, Zhao-Kui Wan, Luoheng Qin, Qian Liu, Wing Shun Cheung
  • Publication number: 20230192667
    Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 22, 2023
    Inventors: Xin CHENG, Yingtao LIU, Luoheng QIN, Feng REN, Jianping WU
  • Publication number: 20230183210
    Abstract: The disclosure provides for small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. The disclosure further provides methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating diseases or disorders related to USP1, such as cancer.
    Type: Application
    Filed: February 6, 2023
    Publication date: June 15, 2023
    Inventors: Jianping Wu, Luoheng Qin, Jinxin Liu
  • Publication number: 20220340598
    Abstract: The invention relates to new pyrazolopyridinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: June 10, 2022
    Publication date: October 27, 2022
    Inventors: Haibing GUO, Zhao-Kui WAN, Luoheng QIN, Qian LIU, Wing Shun CHEUNG
  • Patent number: 11384075
    Abstract: The invention relates to new quinolinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: July 12, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Haibing Guo, Zhao-Kui Wan, Luoheng Qin, Qian Liu, Wing Shun Cheung
  • Patent number: 11384099
    Abstract: Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: July 12, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Haibing Guo, Zhao-Kui Wan, Luoheng Qin, Qian Liu, Wing Shun Cheung
  • Publication number: 20220213123
    Abstract: The invention relates to new thienopyridinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 25, 2019
    Publication date: July 7, 2022
    Inventors: Luoheng QIN, Zhao-Kui WAN, Haibing GUO, Qian LIU
  • Publication number: 20210147411
    Abstract: Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: November 23, 2018
    Publication date: May 20, 2021
    Inventors: Haibing GUO, Zhao-Kui WAN, Luoheng QIN, Qian LIU, Wing Shun CHEUNG